Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10391093

    Therapeutic compounds

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10391095

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10391097

    Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

    VTV THERAPEUTICS LLC · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10391098

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10391142

    Biomarkers for painful intervertebral discs and methods of use thereof

    The Regents of the University of California · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10391112

    Cationic polymers as co-drugs for chemotherapeutic agents

    Northwestern University · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10391116

    Polyvalent RNA-nanoparticle compositions

    Northwestern University · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10391143

    Mitochondrial-derived peptide MOTS3 regulates metabolism and cell survival

    The Regents of the University of California · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10391152

    Methods of using a fixed dose of a clotting factor

    BIOVERATIV THERAPEUTICS INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10392368

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10391157

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10391183

    Infectivity-enhanced conditionally-replicative adenovirus and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10391170

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10391175

    BET bromodomain inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10392365

    Antifungal compound process

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10392379

    Hepatitis B core protein modulators

    ASSEMBLY BIOSCIENCES, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10392386

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10392391

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10392412

    Platinum anticancer agents

    The Regents of the University of California · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10392430

    Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10392432

    Human antibodies to influenza hemagglutinin

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10392434

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10392441

    IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia

    UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10392618

    Micro-RNA family that modulates extracellular matrix genes and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10392642

    High molecular weight heparosan polymers and methods of production and use thereof

    The Board of Regents of the University of Oklahoma · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10391126

    CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA

    The Board of Regents of the University of Texas System · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10391164

    Vaccines for HSV-2

    IMMUNE DESIGN CORP. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10392376

    Heterocyclic inhibitors of ATR kinase

    The Board of Regents of the University of Texas System · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10392439

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10391075

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10398668

    Glutamate treatment of cardiovascular disorders

    The Board of Regents of the University of Oklahoma · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10401361

    Intracellular organelle peptide targeted enzyme substrates

    Marker Gene Technologies, Inc · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10398706

    Heteroaryldiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10400253

    Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10399962

    Azolopyrimidine for the treatment of cancer-related disorders

    Arcus Biosciences, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10398776

    Phonophoretic cannabidiol composition and transdermal delivery system

    Essential Green Goodness LLC · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10399937

    Ionizable cationic lipid for RNA delivery

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10398778

    Method for enhancing specific immunotherapies in cancer treatment

    Providence Health & Services—Oregon · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10399994

    Compounds and methods for preventing or treating sensory hair cell death

    Oricula Therapeutics LLC · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10398662

    GHB formulation and method for its manufacture

    JAZZ PHARMA IRELAND LIMITED · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10398680

    Methods of treating muscular dystrophy

    BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10400015

    Recombinant HIV-1 envelope proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10398734

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10398749

    Methods of treating muscular dystrophy

    BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10399943

    Antifungal compound process

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10400239

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10400238

    Polynucleotide agents targeting complement component C5 and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10400045

    Internalizing human monoclonal antibodies targeting prostate and other cancer cells

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.